Date: 2016-09-28
Type of information: Nomination
Compound:
Company: Medday (France)
Therapeutic area: CNS diseases - Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 2016, MedDay, a biotechnology company focused on the treatment of nervous system disorders, announced the appointment of Janet Vergis and George M. Garibaldi M.D. as independent Non-Executive Directors to its Board, with immediate effect.
Janet Vergis has more than 25 years’ experience in the healthcare industry with a strong track record with growing businesses. She currently serves as an Executive Advisor to private equity firms and was most recently Chief Executive Officer of OraPharma, Inc. where she led the successful turnaround and subsequent sale of the company. Prior to these roles, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceutica, McNeil Pediatrics, and Ortho-McNeill Neurologics. During her five years as President she led over 1,700 employees to deliver double-digit increases in revenue and profit across the three companies. Vergis currently serves on the Board of Directors for Church and Dwight Co., Inc. and Impax Laboratories, Inc., is Chairman of the Biotech Advisory Board and a Member of The Dean’s Advisory Counsel for The Eberly College of Science at The Pennsylvania State University.
Dr George M. Garibaldi has more than 25 years’ global pharmaceutical and academic experience in early to late-stage drug development specialising in small and large molecules, sporadic and rare diseases, leading to multiple product approvals in the area of neurology and psychiatry. Most recently, Dr Garibaldi was Vice President of Neuroscience and Product Development, at Hoffmann-La Roche AG, where he successfully designed, implemented and executed three Phase III programs in Primary and Relapsing Remitting multiple sclerosis (Ocrelizumab), schizophrenia and Alzheimer’s disease. Previously Dr Garibaldi worked for Janssen Pharmaceuticals, LLC as Therapy Area Lead, Neuroscience, and for Novartis as Executive Director, specialising in nervous system clinical research and development. He is the Founder and previous President of the International Society for CNS Clinical Trials and Methodology (ISTCM) and is currently the Chairman of the International Society of CNS Drug Development (ISCDD). In these roles, he promotes advancing trial methodology and paving the roads for novel approaches to enhancing research outcomes in diseases of the nervous system. He is a Member of the Collegium Internationale Neuro-psychopharmacologicum (CINP) and of the American Academy of Child and Adolescent psychiatry.
Financial terms:
Latest news:
